Phase II trial of encapsulated rapamycin to reduce polyp burden associated with familial adenomatous polyposis [0.03%]
包裹型雷帕霉素降低家族性腺瘤性肠息肉病相关息肉负荷II期临床试验
Joseph C Broderick,Niloy Jewel Samadder,Elena Stoffel et al.
Joseph C Broderick et al.
Purpose: Familial adenomatous polyposis (FAP) confers a significant risk of colorectal/duodenal cancer. Encapsulated rapamycin (eRapa) has demonstrated promise as FAP chemoprevention in early clinical studies. ...
A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple Negative Breast Cancer [0.03%]
一项评价新辅助系统治疗三阴性乳腺癌早期疗效的FLT-PET与FDG-PET随机二期临床试验
Melek Akay,Jennifer Glendenning,Holly Tovey et al.
Melek Akay et al.
Purpose: Early identification of response to neoadjuvant chemotherapy (NACT) in triple negative breast cancer (TNBC) can facilitate timely treatment adjustments. This phase II analytical and clinical validity study (TNPET...
The SOS1 inhibitor BI 1701963 as monotherapy or in combination with trametinib in patients with KRAS mutation-positive solid tumors [0.03%]
针对携带KRAS突变的实体瘤患者单用或与曲马替尼联用SOS1抑制剂BI 1701963的研究
Pasi A Jänne,Melissa L Johnson,Jin Li et al.
Pasi A Jänne et al.
Background: BI 1701963 is a small molecule son of sevenless 1 (SOS1) inhibitor which selectively binds to SOS1, blocking the protein-protein interaction of SOS1 with guanosine diphosphate-bound RAS (rat sarcoma virus) pro...
Fingerprinting the Metabolic and Lipidomic Landscapes of Pancreatic Ductal Adenocarcinoma with MALDI Imaging [0.03%]
基于MALDI成像的胰腺导管腺癌代谢及脂质组指纹图谱研究
Saleem Yousf,Kristine Glunde,Dalton R Brown et al.
Saleem Yousf et al.
Purpose: Metabolic reprogramming plays an integral role in progression, immune evasion, and response to treatment in many cancers, including pancreatic ductal adenocarcinoma (PDAC). This study aimed to spatially character...
Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastoma [0.03%]
Ipatasertib联合Atezolizumab在实体瘤和难治性胶质母细胞瘤中增强PI3K / AKT通路免疫反应的I期临床试验
Crescens Tiu,Wing Yau,Diogo Silva et al.
Crescens Tiu et al.
Purpose: Activation of the phosphatodylinositol-3-kinase/AKT (PI3K/AKT) signalling pathway promotes tumor immune evasion by suppressing effector T-cell infiltration and enhancing regulatory T-cell activity contributing to...
Katharina Lueckerath,Boris Hadaschik,Ken Herrmann et al.
Katharina Lueckerath et al.
Radioligand therapy exemplifies precision oncology, yet its consequences remain incompletely understood. A recent article shows that [177Lu]Lu-PSMA promotes emergence and expansion of clonal hematopoiesis enriched for DNA damage response ge...
Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial [0.03%]
一项II期MoST-CIRCUIT试验：纳武利尤单抗和伊匹木单抗联合治疗晚期肝内胆管癌及胆囊癌患者的效果
Adnan Nagrial,Matteo S Carlino,Ashray Gunjur et al.
Adnan Nagrial et al.
Purpose: Anti-PD-1/PD-L1 blockade combined with chemotherapy has become first line treatment for advanced biliary tract cancers (BTC). Combined anti-PD-1/CTLA-4 blockade using nivolumab and ipilimumab has shown encouragin...
A urinary three-metabolite signature enables non-invasive identification of high-risk ovarian cancer patients [0.03%]
基于尿液代谢标志物的高危卵巢癌患者的非侵入性识别模型
Alexander Max Funk,Mareike Brieske,Franziska Maria Schwarz et al.
Alexander Max Funk et al.
Background: Reliable prognostic tools in ovarian cancer are urgently needed to guide risk-adapted treatment decisions, yet the clinical utility of urinary metabolites for non-invasive risk stratification remains largely u...
Returning to PARP inhibition: Rechallenge with Bevacizumab in Ovarian Cancer [0.03%]
卵巢癌患者重新使用PARP抑制剂及贝伐单抗的治疗尝试
Manavi Sachdeva,David S P Tan
Manavi Sachdeva
The KGOG 3056/NIRVANA-R trial demonstrated that niraparib rechallenge combined with bevacizumab may potentially be a promising maintenance strategy in patients with platinum-sensitive recurrent ovarian cancer (PSROC) previously treated with...
Integrated Multiomic Profiling Enhances Risk Stratification and Prognostication in Canine Osteosarcoma [0.03%]
整合的多组学谱型提高犬骨肉瘤的风险分层和预后判断能力
Anjali Garg,Joshua D Mannheimer,Heather Gardner et al.
Anjali Garg et al.
Purpose: Osteosarcoma is a heterogeneous and aggressive primary bone malignancy that affects both canines and humans. Standardized treatment regimens prescribed to both species do not address the complexity of the disease...